Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

777
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
777
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.2K
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

611
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
611
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

65
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

588
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
588
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

808
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
808

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tobacco-derived particulates and the periodontal axis: Distinct cytotoxic and stress-related mechanisms in human gingival fibroblasts.

Scientific reports·2026
Same author

The first link between ADAMTS-13 and apoptosis in type 1 diabetic liver injury.

Histochemistry and cell biology·2025
Same author

[Informed consent in radiotherapy care].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2024
Same author

The association of microRNAs in the development of retinopathy of prematurity.

Journal of neonatal-perinatal medicine·2024
Same author

Stereotactic magnetic resonance imaging-guided radiotherapy for intracardiac metastases: A case report.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2024
Same author

Indication of radiotherapy for de novo metastatic cancer. The « Recommendations » Commission first issue.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2024

Related Experiment Video

Updated: Mar 19, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Aromatase inhibitors decrease radiation-induced lung fibrosis: Results of an experimental study.

A Y Altinok1, S Yildirim2, T Altug3

  • 1Department of Radiation Oncology, Medipol University, Medical School, TEM Avrupa Otoyolu Goztepe cikisi, No:1 Bagcilar, Istanbul, Turkey.

Breast (Edinburgh, Scotland)
|June 22, 2016
PubMed
Summary
This summary is machine-generated.

Aromatase inhibitors (AI) significantly reduced radiation-induced lung fibrosis in rats, offering a protective effect. This suggests AI may mitigate lung damage from radiation therapy in cancer treatment.

Keywords:
Aromatase inhibitorsBreast cancerRadiation therapyRadioprotective effect

More Related Videos

Establishment of a Robust and Reproducible Model of Radiation-Induced Skin and Muscle Fibrosis
07:08

Establishment of a Robust and Reproducible Model of Radiation-Induced Skin and Muscle Fibrosis

Published on: August 31, 2022

2.1K

Related Experiment Videos

Last Updated: Mar 19, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K
Establishment of a Robust and Reproducible Model of Radiation-Induced Skin and Muscle Fibrosis
07:08

Establishment of a Robust and Reproducible Model of Radiation-Induced Skin and Muscle Fibrosis

Published on: August 31, 2022

2.1K

Area of Science:

  • Oncology
  • Radiology
  • Pharmacology

Background:

  • Tamoxifen (TAM) is known to exacerbate radiation-induced lung fibrosis (RILF).
  • Aromatase inhibitors (AI) have demonstrated superiority over TAM in adjuvant therapy.
  • Preclinical studies indicate AI may sensitize cancer cells to radiation.

Purpose of the Study:

  • To investigate the impact of AI on the development of RILF in a rat model.
  • To compare the effects of different AI (anastrozole, letrozole, exemestane) on RILF.

Main Methods:

  • 60 female Wistar-albino rats were divided into six groups: Control, RT alone, RT + TAM, RT + Anastrozole (ANA), RT + Letrozole (LET), and RT + Exemestane (EXE).
  • Radiation therapy (RT) involved 30 Gy in 10 fractions to both lungs.
  • AI doses were calculated based on rat weight and administered orally; fibrosis was quantified using histological analysis and image analysis.

Main Results:

  • RT alone significantly increased lung fibrosis compared to the control group (5.9 vs 1.7).
  • Tamoxifen (TAM) did not significantly increase RILF.
  • All AI groups (ANA, LET, EXE) showed significantly less lung fibrosis than RT alone or RT + TAM groups (p < 0.001).
  • RT + AI groups exhibited fibrosis levels similar to the control group.

Conclusions:

  • Aromatase inhibitors (AI) demonstrate a protective effect against radiation-induced lung fibrosis.
  • AI significantly decrease RILF, bringing fibrosis levels down to those observed in the control group.
  • These findings suggest AI could be beneficial in mitigating lung toxicity associated with radiation therapy.